Fads3 Antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | Q8K1P9 |
Other Accession | NM_173137, NP_775160 |
Reactivity | Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog |
Predicted | Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 49kDa |
Gene ID | 286922 |
---|---|
Other Names | Fatty acid desaturase 3, 1.14.19.-, Fads3 |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-Fads3 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | Fads3 Antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Fads3 {ECO:0000303|PubMed:19752397, ECO:0000303|PubMed:24070791} |
---|---|
Function | Mammals have different sphingoid bases that differ in their length and/or pattern of desaturation and hydroxyl groups. The predominant sphingoid base that comprises mammalian ceramides is sphing-4-enine (sphingosine or SPH) which has a trans (E) desaturation at carbon 4. FADS3 is a desaturase that introduces a cis (Z) double bond between carbon 14 and carbon 15 of the sphingoid base (also known as long chain base, LCB), producing LCBs such as sphinga-4,14-dienine (SPD, d18:2(4E,14Z)) from SPH. Prefers SPH-containing ceramides (N- acylsphing-4-enines) as substrates. Capable of metabolizing also the SPH in its free form. SPD ceramides occur widely in mammalian tissues and cells. Due to their unusual structure containing a cis double bond, SPD ceramides may have an opposite, negative role in lipid microdomain formation relative to conventional ceramides. Could be involved in the detoxification of 1-deoxy sphingolipids, by desaturating the cytotoxic 1-deoxysphinganine (1-deoxySA, m18:0), produced under pathological conditions, to 1-deoxysphingenine (1-deoxysphingosine, 1-deoxySO, m18:1). Although prefers SPH-containing ceramides (N-acylsphing-4- enines) as substrates, it also exhibits activity toward dihydrosphingosine-containing CERs (N-acylsphinganines) and produces 14Z-SPH-containing sphingolipids. Its desaturase mechanism involves an electron transfer facilitated by cytochrome b5 (By similarity). FADS3 also acts as a methyl-end fatty acyl coenzyme A (CoA) desaturase that introduces a cis double bond between the preexisting double bond and the terminal methyl group of the fatty acyl chain. Desaturates (11E)- octadecenoate (trans-vaccenoate, the predominant trans fatty acid in human milk) at carbon 13 to generate (11E,13Z)-octadecadienoate (also known as conjugated linoleic acid 11E,13Z-CLA) (PubMed:24070791, PubMed:30262139). |
Cellular Location | Endoplasmic reticulum membrane {ECO:0000250|UniProtKB:Q9Y5Q0}; Multi-pass membrane protein |
Tissue Location | Essentially expressed in liver and kidney and to a lesser extent in heart, adipose tissue, stomach and pancreas (at protein level) (PubMed:19752397). Higher expression in lactating mammary gland than in liver (PubMed:30262139) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
D'Andrea S.,et al.Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.